ADOPT Phase 4 Interim Analysis: Avatrombopag in Chronic ITP
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, posted on LinkedIn:
”ADOPT Phase 4 interim analysis: Avatrombopag in chronic ITP
Pleased to share this ASH poster as one of the co-authors. The interim dataset provides useful real-world evidence on avarombopag efficacy and safety in clinical practice.
Study overview:
– 199 patients | Mean 9.7 years from ITP diagnosis to enrollment
– 52.3 weeks median avarombopag dosing duration
– 44.1 cumulative weeks with platelet counts ≥30×10⁹/L
– 59.3% had received prior TPO-RA therapy—reflecting a population with established disease
Health-related quality of life outcomes:
→ EQ-5D-5L: improvements in mobility, usual activities, and pain/discomfort from enrollment to month 12
→ FACIT-Fatigue scores: consistent improvement across follow-up
→ WPAI: measurable reductions in work absenteeism, presenteeism, and overall impairment
→ ITP-PAQ: higher scores at month 12 across multiple scales
Safety findings:
18.1% adverse event rate | 12.6% serious AEs | 5.5% treatment-related AEs | 2.0% discontinued due to AEs
The data demonstrates sustained platelet control alongside functional improvements in work and daily activities. This aligns with our broader understanding of how effective haemostatic management translates to patient-reported outcomes.
The full analysis continues. Worth reviewing if you’re managing patients on TPO-RA therapy or evaluating treatment efficacy beyond platelet counts alone. ”
Stay updated with Hemostasis Today.
-
Mar 16, 2026, 07:26James Crowley, Professor of Medicine emeritus at Brown University, posted on LinkedIn:
-
Mar 15, 2026, 15:55Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 2
-
Mar 15, 2026, 14:09Abdul Mannan: A Red Eye, a Blood Clot, and Ibrutinib – The Clinical Tightrope
-
Mar 15, 2026, 14:02Denise M: Precision Hemostasis in Patient Blood Management
-
Mar 15, 2026, 13:57Abdulrahman Nasiri: D14 Bone Marrow Biopsy in AML Induction in the Era of Targeted Therapies
-
Mar 15, 2026, 13:52Valentin Ortiz-Maldonado: High-Impact Innovation in CAR-T Therapy Can Emerge From Academic Programmes
-
Mar 15, 2026, 13:45Tareq Abadl: Has Anyone Here Ever Taken an ALP Test Before?
-
Mar 14, 2026, 21:30Ayman Elbadawi: Why Does Stent Thrombosis Still Occur? Insights from the NCDR Data
-
Mar 14, 2026, 20:03Edward Adomako: Recognizing Thrombotic Thrombocytopenic Purpura as A Life-Threatening Emergency